{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:14:10Z","timestamp":1786986850266,"version":"build-2736575974"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Laboratory Medicine"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.cll.2025.01.013","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T08:35:15Z","timestamp":1742373315000},"page":"305-314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Testing Strategies and the Emergence of Designer Benzodiazepines"],"prefix":"10.1016","volume":"45","author":[{"given":"Lindsay A.L.","family":"Bazydlo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas E.","family":"Larkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cll.2025.01.013_bib1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/164_2018_154","article-title":"Designer benzodiazepines: another class of new psychoactive substances","volume":"252","author":"Moosmann","year":"2018","journal-title":"Handb Exp Pharmacol"},{"issue":"4","key":"10.1016\/j.cll.2025.01.013_bib2","doi-asserted-by":"crossref","first-page":"686","DOI":"10.2105\/AJPH.2016.303061","article-title":"Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996-2013","volume":"106","author":"Bachhuber","year":"2016","journal-title":"Am J Public Health"},{"issue":"1","key":"10.1016\/j.cll.2025.01.013_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.7399","article-title":"Patterns in outpatient benzodiazepine prescribing in the United States","volume":"2","author":"Agarwal","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cll.2025.01.013_bib4","first-page":"1","article-title":"Physician office visits at which benzodiazepines were prescribed: findings from 2014-2016 national ambulatory medical care survey","volume":"137","author":"Santo","year":"2020","journal-title":"Natl Health Stat Report"},{"issue":"2","key":"10.1016\/j.cll.2025.01.013_bib5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1176\/appi.ps.201800321","article-title":"Benzodiazepine use and misuse among adults in the United States","volume":"70","author":"Maust","year":"2019","journal-title":"Psychiatr Serv"},{"issue":"2","key":"10.1016\/j.cll.2025.01.013_bib6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/17512433.2023.2170349","article-title":"Designer benzodiazepines: an update","volume":"16","author":"Yu","year":"2023","journal-title":"Expet Rev Clin Pharmacol"},{"key":"10.1016\/j.cll.2025.01.013_bib7","series-title":"Perspectives on drugs: the misuse of benzodiazepines among high-risk opioid users in Europe","year":"2018"},{"key":"10.1016\/j.cll.2025.01.013_bib8","series-title":"New benzodiazepines in Europe \u2013 a review","year":"2021"},{"issue":"1","key":"10.1016\/j.cll.2025.01.013_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/pharmacy12010013","article-title":"Benzodiazepine boom: tracking etizolam, pyrazolam, and flubromazepam from pre-UK psychoactive act 2016 to present using analytical and social listening techniques","volume":"12","author":"Mullin","year":"2024","journal-title":"Pharmacy"},{"issue":"6","key":"10.1016\/j.cll.2025.01.013_bib10","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/eurpub\/ckac161","article-title":"Evidence of the emergence of illicit benzodiazepines from online drug forums","volume":"32","author":"Sarker","year":"2022","journal-title":"Eur J Public Health"},{"issue":"4","key":"10.1016\/j.cll.2025.01.013_bib11","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1080\/15563650.2018.1510502","article-title":"Designer benzodiazepines: a report of exposures recorded in the National Poison Data System, 2014-2017","volume":"57","author":"Carpenter","year":"2019","journal-title":"Clin Toxicol"},{"issue":"8","key":"10.1016\/j.cll.2025.01.013_bib12","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/jat\/bkad036","article-title":"Increasing prevalence of designer benzodiazepines in impaired driving: a 5-year analysis from 2017 to 2021","volume":"47","author":"Papsun","year":"2023","journal-title":"J Anal Toxicol"},{"issue":"34","key":"10.1016\/j.cll.2025.01.013_bib13","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.15585\/mmwr.mm7034a4","article-title":"Notes from the field: illicit benzodiazepines detected in patients evaluated in emergency departments for suspected opioid overdose - four states, October 6, 2020-March 9, 2021","volume":"70","author":"Aldy","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"10.1016\/j.cll.2025.01.013_bib14","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/jat\/bkad004","article-title":"Designer benzodiazepines gidazepam and desalkygidazepam (bromonordiazepam): what do we know?","volume":"47","author":"Maskell","year":"2023","journal-title":"J Anal Toxicol"},{"issue":"3","key":"10.1016\/j.cll.2025.01.013_bib15","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3390\/neurolint14030053","article-title":"Novel designer benzodiazepines: comprehensive review of evolving clinical and adverse effects","volume":"14","author":"Edinoff","year":"2022","journal-title":"Neurol Int"},{"key":"10.1016\/j.cll.2025.01.013_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/2045125320967197","article-title":"New psychoactive substances: a review and updates","volume":"10","author":"Shafi","year":"2020","journal-title":"Ther Adv Psychopharmacol"},{"issue":"1","key":"10.1016\/j.cll.2025.01.013_bib17","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s11419-021-00591-w","article-title":"A case of fatal multidrug intoxication involving flualprazolam: distribution in body fluids and solid tissues","volume":"40","author":"Giorgetti","year":"2022","journal-title":"Forensic Toxicol"},{"issue":"8","key":"10.1016\/j.cll.2025.01.013_bib18","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/jat\/bkae059","article-title":"A postmortem case report involving fentanyl, desalkylgidazepam and bromazolam","volume":"48","author":"Ballotari","year":"2024","journal-title":"J Anal Toxicol"},{"issue":"4","key":"10.1016\/j.cll.2025.01.013_bib19","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/PAF.0000000000000803","article-title":"Clonazolam intoxication case report: danger of designer benzodiazepines","volume":"43","author":"Moore","year":"2022","journal-title":"Am J Forensic Med Pathol"},{"key":"10.1016\/j.cll.2025.01.013_bib20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jpeds.2020.12.075","article-title":"\u201cPressed\u201d etizolam","volume":"232","author":"Love","year":"2021","journal-title":"J Pediatr"},{"issue":"1","key":"10.1016\/j.cll.2025.01.013_bib21","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1373\/jalm.2017.025387","article-title":"Novel benzodiazepines (clonazolam and flubromazolam) identified in candy-like pills","volume":"3","author":"Pope","year":"2018","journal-title":"J Appl Lab Med"},{"issue":"1","key":"10.1016\/j.cll.2025.01.013_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jat\/bkac017","article-title":"The evolution toward designer benzodiazepines in drug-facilitated sexual assault cases","volume":"47","author":"P\u00e9rez","year":"2023","journal-title":"J Anal Toxicol"},{"issue":"4","key":"10.1016\/j.cll.2025.01.013_bib23","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/dta.2003","article-title":"Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays","volume":"9","author":"Bergstrand","year":"2016","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.cll.2025.01.013_bib24","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/jat\/bkab108","article-title":"Urine drug screening in the era of designer benzodiazepines: comparison of three immunoassay platforms, LC-QTOF-MS and LC-MS-MS","volume":"46","author":"Puzyrenko","year":"2022","journal-title":"J Anal Toxicol"},{"issue":"1","key":"10.1016\/j.cll.2025.01.013_bib25","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3390\/molecules27010112","article-title":"Comparison of two immunoassay screening methods and a LC-MS\/MS in detecting traditional and designer benzodiazepines in urine","volume":"27","author":"Rossi","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.cll.2025.01.013_bib26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.clinms.2018.08.004","article-title":"Urine analysis of 28 designer benzodiazepines by liquid chromatography- high-resolution mass spectrometry","volume":"10","author":"Bergstrand","year":"2018","journal-title":"Clin Mass Spectrom"},{"key":"10.1016\/j.cll.2025.01.013_bib27","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11419-013-0187-4","article-title":"Characterization of the designer benzodiazepine pyrazolam and its detectability in human serum and urine","volume":"31","author":"Moosmann","year":"2013","journal-title":"Forensic Toxicol"},{"issue":"2","key":"10.1016\/j.cll.2025.01.013_bib28","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/dta.2480","article-title":"Detection of the designer benzodiazepine flunitrazolam in urine and preliminary data on its metabolism","volume":"11","author":"Ameline","year":"2019","journal-title":"Drug Test Anal"},{"issue":"7","key":"10.1016\/j.cll.2025.01.013_bib29","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/dta.2099","article-title":"Detection of the designer benzodiazepine metizolam in urine and preliminary data on its metabolism","volume":"9","author":"Kintz","year":"2016","journal-title":"Drug Test Anal"},{"issue":"11","key":"10.1016\/j.cll.2025.01.013_bib30","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/jms.3279","article-title":"Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics","volume":"48","author":"Moosmann","year":"2013","journal-title":"J Mass Spectrom"},{"issue":"1","key":"10.1016\/j.cll.2025.01.013_bib31","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/dta.2203","article-title":"Flubromazolam \u2013 basic pharmacokinetic evaluation of a highly potent designer benzodiazepine","volume":"10","author":"Huppertz","year":"2017","journal-title":"Drug Test Anal"},{"issue":"7\u20138","key":"10.1016\/j.cll.2025.01.013_bib32","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/dta.1628","article-title":"Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics","volume":"6","author":"Moosmann","year":"2014","journal-title":"Drug Test Anal"},{"issue":"5","key":"10.1016\/j.cll.2025.01.013_bib33","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/jat\/bkab013","article-title":"The development and validation of a novel designer benzodiazepines panel by LC-MS-MS","volume":"45","author":"Mastrovito","year":"2021","journal-title":"J Anal Toxicol"},{"issue":"1","key":"10.1016\/j.cll.2025.01.013_bib34","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/jat\/bkaa059","article-title":"Quantification of 54 benzodiazepines and z-drugs including 20 designer ones, in plasma","volume":"45","author":"Degreef","year":"2021","journal-title":"J Anal Toxicol"},{"issue":"8","key":"10.1016\/j.cll.2025.01.013_bib35","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/jat\/bkac044","article-title":"Fast and sensitive method for the determination of 17 designer benzodiazepines in hair by liquid chromatography-tandem mass spectrometry","volume":"46","author":"DeFreitas","year":"2022","journal-title":"J Anal Toxicol"},{"key":"10.1016\/j.cll.2025.01.013_bib36","unstructured":"Available at: https:\/\/www.cfsre.org\/nps-discovery\/trend-reports\/nps-benzodiazepines\/report\/49?trend_type_id=1 (Accessed 6 September 2024)."},{"issue":"8","key":"10.1016\/j.cll.2025.01.013_bib37","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1111\/add.16520","article-title":"The surge of bromazolam-related fatalities replacing other novel designer benzodiazepines-related fatalities in San Francisco","volume":"119","author":"Rodda","year":"2024","journal-title":"Addiction"},{"issue":"6","key":"10.1016\/j.cll.2025.01.013_bib38","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3390\/ph14060560","article-title":"Designer benzodiazepines: a review of toxicology and public health risks","volume":"14","author":"Brunetti","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.cll.2025.01.013_bib39","unstructured":"Drug Enforcement Agency, Schedules of controlled substances: temporary placement of etizolam, flualprazolam, clonazepam, flubromazolam and diclazepam in schedule I. 21 CFR Part 1308, 2023. Fedaral Register, Available at: https:\/\/www.federalregister.gov\/documents\/2023\/07\/26\/2023-15748\/schedules-of-controlled-substances-temporary-placement-of-etizolam-flualprazolam-clonazolam."}],"container-title":["Clinics in Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271225000149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271225000149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T06:46:03Z","timestamp":1746773163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272271225000149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0272271225000149"],"URL":"https:\/\/doi.org\/10.1016\/j.cll.2025.01.013","relation":{},"ISSN":["0272-2712"],"issn-type":[{"value":"0272-2712","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Testing Strategies and the Emergence of Designer Benzodiazepines","name":"articletitle","label":"Article Title"},{"value":"Clinics in Laboratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cll.2025.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}